12407 N. MOPAC EXPY., AUSTIN, TX
Market cap: $45.7M (1/09/2025)
Price: $2.11
Rein Therapeutics Terminates Pre-Paid Advance and Standby Equity Agreements
Rein Therapeutics Enters $6 Million Pre-Paid Advance Agreement with Yorkville
Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Other Events
News
Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
News, Legal Opinion, Material Contracts
Shareholder votes
Q3
Q1
Amended Annual Report
FY 2024
Notice of Late Filing for Annual Report
Q2
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Free Writing Prospectus
Correspondence
Submission Upload